Participants were randomly designated to receive one of three remedies: acupuncture, sham acupuncture, or participation in a control group that adopted the Arthritis Foundation’s self-help program for managing their condition. Patients continuing to receive standard health care from their main physicians, including anti-inflammatory medications, such as for example COX-2 selective inhibitors, non-steroidal anti-inflammatory medications, and opioid discomfort relievers.The analysis was another line, combination study in sufferers with EGFRm advanced NSCLC who have acquired resistance to first line IRESSA. The IMPRESS study was designed to compare the safety and efficacy of continuing IRESSA, coupled with cisplatin and pemetrexed up to six cycles , versus comparator placebo, coupled with cisplatin and pemetrexed up to six cycles following a development of resistance to first range treatment gefitinib. The analysis did not meet its primary endpoint of a statistically significant improvement in PFS. The secondary endpoint of overall survival continues to be ongoing. At the principal endpoint of PFS analysis, the OS was immature and had not been conclusive. Longer OS was suggested for the placebo plus cisplatin and pemetrexed arm, versus the IRESSA plus cisplatin and pemetrexed arm.